Gilead Combination Cut Hepatitis Virus in Study, RBC Says
This article is for subscribers only.
Gilead Sciences Inc.’s four-drug combination eliminated hepatitis C virus in patients in an early-stage study, RBC Capital Markets LLC analysts said.
The findings support an ongoing mid-stage study of the combination, the analysts, led by Michael Yee in San Francisco, wrote yesterday in a note to investors, citing an abstract of the trial. The analysts said they expect data next year from a mid-stage study by the Foster City, California-based company.